Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop.

Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop. Abstract Text:

Michael Krams,Carl-Fredrik Burman,Vladimir Dragalin,Brenda Gaydos,Andrew P Grieve,Jose Pinheiro,Willi Maurer,Michael Krams,Carl-Fredrik Burman,Vladimir Dragalin,Brenda Gaydos,Andrew P Grieve,Jose Pinheiro,Willi Maurer,Michael Krams,Carl-Fredrik Burman,Vladimir Dragalin,Brenda Gaydos,Andrew P Grieve,Jose Pinheiro,Willi Maurer,Michael Krams,Carl-Fredrik Burman,Vladimir Dragalin,Brenda Gaydos,Andrew P Grieve,Jose Pinheiro,Willi Maurer,Paul Gallo,

This paper provides reflections on the opportunities, scope and challenges of adaptive design as discussed at PhRMA's workshop held in November 2006. We also provide a status report of workstreams within PhRMA's working group on adaptive designs, which were triggered by the November workshop. Rather than providing a comprehensive review of the presentations given, we limit ourselves to a selection of key statements. The authors reflect the position of PhRMA's working group on adaptive designs.

Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop. Publishing Authors By Initials

M Krams,CF Burman,V Dragalin,B Gaydos,AP Grieve,J Pinheiro,W Maurer,M Krams,CF Burman,V Dragalin,B Gaydos,AP Grieve,J Pinheiro,W Maurer,M Krams,CF Burman,V Dragalin,B Gaydos,AP Grieve,J Pinheiro,W Maurer,M Krams,CF Burman,V Dragalin,B Gaydos,AP Grieve,J Pinheiro,W Maurer,P Gallo,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of biopharmaceutical statistics

VOLUME: 17

Page Numbers: 957-64

Journal Abbreviation:

ISSN: 1054-3406

DAY: 20

MONTH: 11

YEAR: 2007

Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9200436

Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop.

AFFILIATION: Wyeth Research, Collegeville, Pennsylvania, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Biopharm Stat

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop Related Publications

• Acquired cold urticaria symptoms can be safely prevented by ebastine.
• Adaptive Designs in Clinical Drug Development: Opportunities, Challenges, and Scope Reflections Following PhRMA's November 2006 Workshop.
• Assessing combinations of cytotoxic agents using leukemia cell lines.
• Cell-permeable peptides induce dose- and length-dependent cytotoxic effects.
• Depression and functional impairment independently contribute to decreased quality of life in cancer patients prior to chemotherapy.
• Do All Patients with Community-acquired Pneumonia Need Antibiotics Within 4 Hours of Presentation?
• Early detection of schizophrenia: current evidence and future perspectives.
• Egg labeling methods for gastric emptying scintigraphy are not equivalent in producing a stable solid meal.
• Employing mutants to study thrombin residues responsible for factor XIII activation peptide recognition: a kinetic study.
• Exposure of bovine embryos to trypsin during washing does not decrease embryonic survival.
• Highly Efficient Enzymatic Synthesis of 2-Monoacylglycerides and Structured Lipids and their Production on a Technical Scale.
• Improving state pain policies: recent progress and continuing opportunities.
• Information fusion in biomedical image analysis: combination of data vs. combination of interpretations.
• Metabolism and toxicological detection of the designer drug 4-iodo-2,5-dimethoxy-amphetamine (DOI) in rat urine using gas chromatography-mass spectrometry.
• Modelling socioeconomic and health determinants of health-care use: a semiparametric approach.
• Nuclear medicine training for radiology residents: needs assessment survey.
• Oxybutynin for hyperhidrosis.
• Perturbations in factor XIII resulting from activation and inhibition examined by solution based methods and detected by MALDI-TOF MS.
• Platelet binding and biodistribution of [99mTc]rBitistatin in animal species and humans.
• Powerful short-cuts for multiple testing procedures with special reference to gatekeeping strategies.
• Preservation of microelastic properties of dentin and tooth enamel in vitro--a scanning acoustic microscopy study.
• Requestioning depression in patients with cancer: Contribution of somatic and affective symptoms to Beck's Depression Inventory.
• Retropubic surgery.
• Shape-based averaging.
• Superovulation and embryo quality in beef cows using PMSG and a monoclonal anti-PMSG.
• The complex morphology of Maurer's clefts: from discovery to three-dimensional reconstructions.
• Validated liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxym
• [In Process Citation]
• [Not Available.]
• [Not Available.]